Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again

Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again

Submitted by admin on November 16, 2020 - 10:42pm
Source: 
Endpoints
News Tags: 
Bristol-Myers Squibb
CVRs
Celgene
M&A
Headline: 
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
snippet: 

The CVR ($BMYRT) tied to Bristol Myers Squibb’s big Celgene buyout took one more step right to the brink Monday afternoon.

Do Not Allow Advertisers to Use My Personal information